CD80 and neoplasm: In mouse models, anti-CTLA-4 mAbs do not block CTLA-4-B7 interaction, yet they remain active in anti-tumor efficacy, suggesting that intratumoral depletion of Tregs by anti-CTLA-4 antibodies might be the primary MOA (172).